Neovascular Age-related Macular Degeneration Clinical Trial
Official title:
A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
This is a randomized, double-masked, placebo-controlled, dose-ranging, multicenter study to assess the efficacy and safety of AKST4290 administered orally at 400 mg b.i.d. or 800 mg b.i.d. in combination with intravitreal aflibercept injections (IAI), in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD) who are naïve to treatment with anti-vascular endothelial growth factor (anti-VEGF) medications in the study eye. Subjects will be treated with AKST4290 800 mg daily, 1600 mg daily, or placebo for a total of 36 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04101877 -
The Sahlgrenska Anti-VEGF Study
|
Phase 2 | |
| Completed |
NCT03953079 -
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
|
Phase 2 | |
| Terminated |
NCT03577899 -
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
|
Phase 3 | |
| Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
| Completed |
NCT01926977 -
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00370539 -
Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD
|
Phase 3 | |
| Recruiting |
NCT03683251 -
Extension Study for the Port Delivery System With Ranibizumab (Portal)
|
Phase 3 | |
| Completed |
NCT03909425 -
Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography
|
||
| Completed |
NCT03744767 -
Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
| Recruiting |
NCT04690556 -
Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD
|
Phase 3 | |
| Completed |
NCT05281042 -
Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
|
||
| Completed |
NCT03677934 -
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
|
Phase 3 | |
| Recruiting |
NCT03594461 -
Intense Treatment Regimen With Intravitreal Aflibercept Injection
|
Phase 1/Phase 2 | |
| Completed |
NCT05131646 -
Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
|
||
| Completed |
NCT04537884 -
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT03216538 -
Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Completed |
NCT04304755 -
Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)
|
Phase 2 | |
| Completed |
NCT01958918 -
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
|
Phase 4 | |
| Active, not recruiting |
NCT01918878 -
Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
|
Phase 4 | |
| Completed |
NCT01712035 -
Neovascular Age-related Macular Degeneration
|